Avidity Biosciences: Looks Tempting, But Wait For Interim Phase 3 Data
Avidity Biosciences specializes in RNA-based therapies using Antibody-oligonucleotide conjugates to deliver drugs directly to ...
Managed Healthcare Executive4d
FDA, EMA See Differences in Cell and Gene Therapy Trial Data
Researchers have suggested that uniform evidence standards and reporting requirements could help speed patient access to cell ...
Managed Healthcare Executive5d
Solid Biosciences Reports Positive Data from DMD Gene Therapy Trial
Solid Biosciences’ gene therapy uses a shortened version of the dystrophin protein, which is engineered to mimic the key functions of full-length dystrophin and allows it be delivered more effectively ...
Solid Biosciences’ stock soars on early success in DMD gene therapy trial
The trial was able to elicit more than double the microdystrophin gene in patients after 90 days of treatment.
Truist Financial Sticks to Its Buy Rating for Solid Biosciences (SLDB)
Truist Financial analyst Joon Lee maintained a Buy rating on Solid Biosciences (SLDB – Research Report) today. The company’s shares closed ...
Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here?
Detailed price information for Solid Biosciences Inc (SLDB-Q) from The Globe and Mail including charting and trades.
Hosted on MSN5d
Solid Biosciences' Retail Following Swells Amid Stock's Best Run In A Year — What's Behind The Move?
Solid Biosciences Inc. (SLDB) shares surged more than 31% on Tuesday, their best session since January 2024, and extended ...
Solid Biosciences stock soars on promising Duchenne therapy data
The trial data, which was reported on February 18, 2025, also suggested potential cardiac benefits from the therapy. The company mentioned that SGT-003 has been well-tolerated with no serious adverse ...